AIMSS评分在2型神经纤维瘤病颅内脑膜瘤快速生长风险中的验证
该回顾性研究纳入92例2型神经纤维瘤病(NF2)患者的358个颅内脑膜瘤,于2012至2018年前瞻性观察并测量肿瘤体积。诊断时肿瘤体积较大、瘤周水肿、无钙化及T2高/等信号与快速生长相关。AIMSS评分在该NF2队列中验证有效,其预测快速生长风险的AUC为0.82(95%CI 0.76-0.88),与作者多因素模型(AUC 0.86,95%CI 0.81-0.91)无统计学差异(p=0.1)。
要点
- AIMSS评分可用于NF2相关脑膜瘤快速生长风险预测,辅助临床决策。
- 诊断时体积大、瘤周水肿、无钙化、T2高/等信号提示快速生长风险。
- 遗传严重度评分未见影响NF2脑膜瘤生长速率。
核心结论
- AIMSS评分在NF2相关脑膜瘤队列中有效,能充分预测快速生长风险,可辅助NF2患者决策。
研究设计与样本
- 回顾性分析2012至2018年前瞻性观察的92例NF2患者共358个测量的颅内脑膜瘤,测量诊断时及每次随访的肿瘤体积。
主要发现
- 多因素分析显示诊断时肿瘤体积较大(p<0.0001)、瘤周水肿(p=0.022)、无钙化(p<0.0001)、T2高/等信号(p<0.005)与快速生长显著相关。
- 遗传严重度评分似乎不影响NF2脑膜瘤生长速率。
- AIMSS预测AUC 0.82(95%CI 0.76-0.88),作者模型AUC 0.86(95%CI 0.81-0.91),差异无统计学意义(p=0.1)。
关键数值与推荐
- 快速生长定义为生长≥2 cm3/年。
- AIMSS预测快速生长风险AUC 0.82(95%CI 0.76-0.88)。
- 作者多因素模型AUC 0.86(95%CI 0.81-0.91),与AIMSS比较p=0.1。
临床怎么用
- 对NF2患者颅内脑膜瘤可应用AIMSS评分评估快速生长风险,结合诊断时体积、瘤周水肿、钙化及T2信号特征辅助制定随访与治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Intracranial meningiomas occur in about half of neurofibromatosis type 2 (NF2) patients and are very frequently multiple. Thus, estimating individual meningiomas' growth rates is of great interest to tailor therapeutic interventions. The Asan Intracranial Meningioma Scoring System (AIMSS) has recently been published to estimate the risk of tumor growth in sporadic meningiomas. The current study aimed to determine predictors of rapid meningioma growth in NF2 patients and to evaluate the AIMSS score in a specific NF2 cohort. METHODS: The authors performed a retrospective analysis of 92 NF2 patients with 358 measured intracranial meningiomas that had been observed prospectively between 2012 and 2018. Tumor volumes were measured at diagnosis and at each follow-up visit. The growth rates were determined and evaluated with respect to the clinicoradiological parameters. Predictors of rapid tumor growth (defined as growth ≥ 2 cm3/yr) were analyzed using univariate followed by multivariate logistic regression to build a dedicated predicting model. Receiver operating characteristic (ROC) curves to predict the risk of rapid tumor growth with the AIMSS versus the authors' multivariate model were compared. RESULTS: Sixty tumors (16.76%) showed rapid growth. After multivariate analysis, a larger tumor volume at diagnosis (p < 0.0001), presence of peritumoral edema (p = 0.022), absence of calcifications (p < 0.0001), and hyperintense or isointense signal on T2-weighted MRI (p < 0.005) were statistically significantly associated with rapid tumor growth. It is particularly notable that the genetic severity score did not seem to influence the growth rate of NF2 meningiomas. In comparison with the AIMSS, the authors' multivariate model's prediction did not show a statistically significant difference (area under the curve [AUC] 0.82 [95% CI 0.76-0.88] for the AIMSS vs AUC 0.86 [95% CI 0.81-0.91] for the authors' model, p = 0.1). CONCLUSIONS: The AIMSS score is valid in the authors' cohort of NF2-related meningiomas. It adequately predicted risk of rapid meningioma growth and could aid in decision-making in NF2 patients.
引用
- Abi Jaoude S, Peyre M, Degos V, et al. Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients. J Neurosurg. 2020. PMID: 32442973. doi:10.3171/2020.3.JNS192382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。